
Oct 26 (Reuters) - Castle Biosciences Inc CSTL.O:
NEW DATA AT AMERICAN COLLEGE OF GASTROENTEROLOGY ANNUAL MEETING SHOW TISSUECYPHER® PROVIDES ACTIONABLE RISK INSIGHTS THAT INFLUENCE CLINICAL MANAGEMENT AND PROMPT RISK-ALIGNED INTERVENTION IN BARRETT’S ESOPHAGUS
CASTLE BIOSCIENCES INC - TISSUECYPHER SHOWS 34% AND 62% FIVE-YEAR PROGRESSION RISK